Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
| Autor: | Sai-Hong Ignatius Ou |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Afatinib Targeted therapy chemistry.chemical_compound Gefitinib Carcinoma Non-Small-Cell Lung Internal medicine medicine Carcinoma Humans heterocyclic compounds Epidermal growth factor receptor Protein Kinase Inhibitors neoplasms Neoplasm Staging Quinazolinones Clinical Trials as Topic biology business.industry Hematology medicine.disease Dacomitinib respiratory tract diseases ErbB Receptors chemistry Drug Resistance Neoplasm Mutation Quinazolines biology.protein Erlotinib business Tyrosine kinase medicine.drug |
| Zdroj: | Critical Reviews in Oncology/Hematology. 83:407-421 |
| ISSN: | 1040-8428 0029-9804 |
| Popis: | The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC. First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. However, resistance to gefitinib and erlotinib invariably develops after prolonged clinical use. Two second-generation irreversible EGFR TKIs, afatinib (BIBW 2992) and dacomitinib (PF-00299804), that can potentially overcome the majority of these resistances are in late stage clinical development. Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect